Consequences of inaccurate hepatitis C virus genotyping on the costs of prescription of direct antiviral agents in an Italian district

Ennio Polilli1
Valeria Cento2
Umberto Restelli3,4
Francesca Ceccherini-Silberstein2
Marianna Aragri3
Velia Chiara Di Maio2
Antonina Sciacca1
Fiorenzo Santoleri5
Paolo Fazii6
Alberto Costantini5
Carlo Federico Perno2
Giustino Parruti1

1Infectious Diseases Unit, Pescara General Hospital, Pescara, Italy; 2Department of Experimental Medicine and Surgery, University of Rome “Tor Vergata”, Rome, Italy; 3CREMS - Centre for Research on Health Economics, Social and Health Care Management, Carlo Cattaneo – LIUC University, Castellanza, Italy; 4School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; 5Hospital Pharmacy, Pescara General Hospital, Italy; 6Microbiology and Virology Unit, Pescara General Hospital, Pescara, Italy

Abstract: Available commercial assays may yield inaccurate hepatitis C virus (HCV) genotype assignment in up to 10% of cases. We investigated the cost-effectiveness of re-evaluating HCV genotype by population sequencing, prior to choosing a direct acting antiviral (DAA) regimen. Between March and September 2015, HCV sequence analysis was performed in order to confirm commercial LiPA-HCV genotype (Versant® HCV Genotype 2.0) in patients eligible for treatment with DAAs. Out of 134 consecutive patients enrolled, sequencing yielded 21 (15.7%) cases of discordant results. For three cases of wrong genotype assignment, the putative reduction in efficacy was gauged between 15% and 40%. Among the eight cases for whom G1b was assigned by commercial assays instead of G1a, potentially suboptimal treatments would have been prescribed. Finally, for five patients with G1 and indeterminate subtype, the choice of regimens would have targeted the worst option, with a remarkable increase in costs, as in the case of the four mixed HCV infections for whom pan-genotypic regimens would have been mandatory. Precise assignment of HCV genotype and subtype by sequencing may, therefore, be more beneficial than expected, until more potent pan-genotypic regimens are available for all patients.

Keywords: HCV, HCV sequence analysis, HCV genotype, direct acting antiviral, treatment costs

Introduction

Currently available genotyping methods, based on reverse hybridization with subtype-specific primers and probes targeting the 5′-untranslated region (5′-UTR) and core regions (Versant® HCV Genotype 2.0 system; Siemens Healthcare Diagnostics, Milan, Italy), as well as real-time PCR assays based on 5′-UTR and NS5B sequencing (Abbott HCV Genotype II assay; Abbott Diagnostics, Lake Forest, IL, USA), accurately differentiate major hepatitis C virus (HCV) genotypes in the majority of cases and are widely used because of their technical simplicity and lower costs.1 Routine genotyping methods, however, may cause wrong, inaccurate, or incomplete assignment in up to 10% of cases, due to indeterminate results, mixed infections, wrong subtyping, and even wrong genotyping, as we recently reported.2 Misclassifications of HCV genotype were described in characterization of genotypes 5 and 6 and in subtyping of genotypes.2–6 Versant HCV Genotype 2.0 fails to identify genotype 1 subtype in 2.2%–7.4% of the cases.2 In particular, cause of misclassification was due to variability of 5′-UTR of HCV. This region is not appropriate for discriminating HCV strains at the subtype level and for distinguishing many genotype 6 samples from genotype 1 as well as for distinguishing subtypes within genotypes 1, 2, and 3.6 Incorrect assignments of genotype were associated with nucleotide polymorphisms in...
the 5′-UTR of HCV that may alter the ability of probe/primer of commercial assays to recognize viral strains. Indeterminate genotype results were reported for changes at positions 166 and 119 in genotype 2b and 138, 108, and 99 in genotype 3h of 5′-UTR of HCV.7 As most of the currently available therapeutic options target HCV genotype 1 strains, treatment of other genotypes, in particular genotype 3, is presently less efficient and more costly when directly acting antivirals (DAAs) are used.8 Reassessment of HCV genotype and subtype by sequencing prior to interferon-free regimens may reduce the risk of treatment failure and consequent undue pharmacological costs driven by inappropriate genotype characterization and may, therefore, turn out quite cost beneficial.2,9 We investigated the cost-effectiveness of re-evaluating HCV genotype by population sequencing, prior to choosing a DAA regimen among currently available options, in a mono-centric Italian cohort.

Methods
Between March, 2015, and September, 2015, at the Liver and Infectious Diseases Units of Pescara General Hospital, Italy, HCV sequence analysis was performed in order to confirm previous commercial assignment by a second-generation LiPA-HCV genotype assay (Versant HCV Genotype 2.0; Siemens Healthcare Diagnostics) in all consecutive candidates to treatment with DAAs. The local Health District Authority was requested to evaluate the possible benefits of the experimental procedure, and found it likely cost-effective and funded 200 consecutive assays for the purpose of this evaluation. Direct population sequencing was, therefore, performed for both NS5A and NS3 HCV genes at the University of Tor Vergata (Rome) through highly efficient home-made protocols as previously reported.2 Expert interpretation of mutations and sequence variants detected was also provided by the same source (University of Rome Tor Vergata) for each patient, to help in choosing the most appropriate and individualized regimen. The turnaround time allowance from sample dispatching to availability of assay results was set at a maximum of 3 weeks, to avoid undue delaying of treatments. For the purpose of the present study, in each case of resolved or discordant HCV genotype and/or subtype after sequencing, we calculated the difference in treatment costs between the most likely prescription that would have been possible on the basis of previously available commercial HCV genotype and subtype only, and the most likely prescription made possible by the availability of sequence results with expert interpretation. Interferon-free regimens were prescribed by attending specialists in accordance with current European Association for the Study of the Liver Guidelines and Italian Regulatory Agency (AIFA) reimbursement requirements.10,11 Sustained virologic response 12 (SVR-12) was defined as undetectable viral load at 12 weeks after treatment. Expected efficacy for each prescribed regimen was derived by currently available published SVR-12 data for selected reference treatments. The costs considered in the analysis are direct medical costs (referred to 2015) related to each prescribed drug and/or regimen, retrieved from the Pharmacy Unit of Pescara General Hospital, and the genotypic test reimbursement received by the hospital from the Regional Health Service (ie, €60 for LiPA-HCV genotype assay and €500 for sequence analysis of HCV genotype). As a consequence, in the analyses of actual costs, reimbursements from the pharmaceutical companies were not considered, as the local pharmacy did not receive any refund sum as of date (February 8, 2016). The cost-effectiveness analysis was conducted considering the aforementioned direct medical costs and efficacy values for each patient in two scenarios: with the use of sequence analysis of HCV genotype vs use of LiPA-HCV genotype assay. The time horizon considered was up to 12 weeks after HCV antiviral therapy conclusion.

To test the robustness of the results, a resampling boot-strappping analysis was performed, simulating 500 cohorts of 134 patients, randomly extracting patients from the base case scenario.

Ethics
The local Health Administrative Board in Chieti-Pescara reviewed in detail the study design, set up by the Infectious Diseases Staff at Pescara General Hospital. The study was thoroughly discussed by the Direzione Generale Strategica della Azienda Unità Sanitaria Locale di Pescara/Comitato Etico di Chieti/Pescara. A final authorization was granted by Direzione Generale Strategica della Azienda Unità Sanitaria Locale di Pescara early in 2015, as documented in issue Deliberazione del Direttore Generale number 319 March 16, 2015. Written informed consent was obtained from all participants.

Results
During the study period, 134 consecutive patients were included. Starting from January 2008, routine genotype and subtype assays were performed by Versant HCV Genotype 2.0. Sequencing yielded discordant or complementary information in 21 (15.7%) cases. Among these, we found three (2.3%) discordant genotypes, nine (6.7%) discordant G1 subtypes, four (3%) mixed infections, and five (3.7%) indeterminate G1 subtypes that were then correctly attributed. Sub-optimal treatment choice due to wrong genotype assessment in the three individual cases would have caused a reduction...
in efficacy which we gauged at our best, based on literature data, as ranging between 17% and 40% (Table 1). G1a was assigned by sequencing instead of G1b by commercial assays in eight out of nine cases with incorrect G1 subtype. This would have caused suboptimal treatment courses, with an expected decrease in efficacy from 5% to 7%. Conversely, in the single opposite case (G1b assignment instead of G1a), the consequence would have been a slight increase in costs and the requirement of ribavirin use (Table 2). For patients with G1 and indeterminate subtype, the choice of regimens would have targeted the subtype 1a option, with a potential sensible increase in costs (Table 2). Finally, the possible consequences of inappropriate prescription due to mixed HCV infections are shown in Table 3. In these cases, pan-genotypic regimens would be mandatory, with an increase in costs up to €32,000 per treatment.

The use of sequence analysis of HCV genotype, compared with LiPA-HCV genotype assay, would lead to a mean increase of efficacy (+1.42%) and per capita costs (+€1,280 per patient). The results of the cost-effectiveness analysis are presented in Table 4.

The 2.4% of the sensitivity analysis simulations led to a dominance of sequence analysis of HCV genotype compared with LiPA-HCV genotype assay, reducing costs and increasing efficacy, while the remaining 97.6% of the results showed an increase in costs and efficacy (between €1,269 and €4,617, and 1.43% and 3.88%) with incremental cost-effectiveness ratios between €845/efficacy unit and €2,009/efficacy unit.

**Discussion**

Although some studies found uninterpretable or indeterminate genotype assignments in varying percentages of assayed samples, especially in non-G1 HCV infections, the possible consequences of HCV genotype misclassification on treatments with DAAs were not yet evaluated and may have been perceived as a minor problem so far. However, in the new scenario of HCV therapy, the costs of genotyping by sequencing are definitely lower than those of DAA regimens, so that even a few treatment failures averted may make reassessing HCV genotype before DAAs very convenient.2 As a consequence, studies aimed at gauging the improvement of treatment outcomes by the systematic deployment of sequence genotype should be encouraged. We introduced mandatory sequencing assays of HCV prior to HCV therapy with DAAs at our site, and compared the results of all consecutive assays performed with previous routine genotype assessments, in an attempt to pinpoint all possible differences in treatment efficacy and on possible parallel cost savings obtained in this way. Although

### Table 1

| Patient META VIR score | Sequence results | Estimated efficacy of treatments prescribed on the basis of Versant HCV Genotype 2.0 assays vs treatments prescribed on sequence analysis results |
|-----------------------|-----------------|------------------------------------------------------------------------------------------------------------------------|
| 1 F2                  | 3a              | Cost-effective treatment based on sequence analysis: 65% (naïve non-cirrhotic patients) vs 69% |
| 2 F4                  | 1a              | Cost-effective treatment based on sequence analysis: 65% (naïve non-cirrhotic patients) vs 69% |
| 3 F2                  | 4               | Cost-effective treatment based on sequence analysis: 65% (naïve non-cirrhotic patients) vs 69% |
| **Notes:**            |                 | *The most likely prescription based on reimbursement allowance rules at AIFA website.** |

**Abbreviations:** AIFA: Italian Regulatory Agency; DCC, discastructor; DAS, dasabuvir; HCV, hepatitis C virus; LDV, ledipasvir; OMB, ombitasvir; PTV, paritaprevir; RBV, ribavirin; Rtv, ritonavir; SIM, simeprevir; SOF, sofosbuvir; wk, weeks.

in efficacy which we gauged at our best, based on literature data, as ranging between 17% and 40% (Table 1). G1a was assigned by sequencing instead of G1b by commercial assays in eight out of nine cases with incorrect G1 subtype. This would have caused suboptimal treatment courses, with an expected decrease in efficacy from 5% to 7%. Conversely, in the single opposite case (G1b assignment instead of G1a), the consequence would have been a slight increase in costs and the requirement of ribavirin use (Table 2). For patients with G1 and indeterminate subtype, the choice of regimens would have targeted the subtype 1a option, with a potential sensible increase in costs (Table 2). Finally, the possible consequences of inappropriate prescription due to mixed HCV infections are shown in Table 3. In these cases, pan-genotypic regimens would be mandatory, with an increase in costs up to €32,000 per treatment.

The use of sequence analysis of HCV genotype, compared with LiPA-HCV genotype assay, would lead to a mean increase of efficacy (+1.42%) and per capita costs (+€1,280 per patient). The results of the cost-effectiveness analysis are presented in Table 4.

The 2.4% of the sensitivity analysis simulations led to a dominance of sequence analysis of HCV genotype compared with LiPA-HCV genotype assay, reducing costs and increasing efficacy, while the remaining 97.6% of the results showed an increase in costs and efficacy (between €1,269 and €4,617, and 1.43% and 3.88%) with incremental cost-effectiveness ratios between €845/efficacy unit and €2,009/efficacy unit.

**Discussion**

Although some studies found uninterpretable or indeterminate genotype assignments in varying percentages of assayed samples, especially in non-G1 HCV infections, the possible consequences of HCV genotype misclassification on treatments with DAAs were not yet evaluated and may have been perceived as a minor problem so far. However, in the new scenario of HCV therapy, the costs of genotyping by sequencing are definitely lower than those of DAA regimens, so that even a few treatment failures averted may make reassessing HCV genotype before DAAs very convenient.2 As a consequence, studies aimed at gauging the improvement of treatment outcomes by the systematic deployment of sequence genotype should be encouraged. We introduced mandatory sequencing assays of HCV prior to HCV therapy with DAAs at our site, and compared the results of all consecutive assays performed with previous routine genotype assessments, in an attempt to pinpoint all possible differences in treatment efficacy and on possible parallel cost savings obtained in this way. Although

### Table 1

| Patient META VIR score | Sequence results | Estimated efficacy of treatments prescribed on the basis of Versant HCV Genotype 2.0 assays vs treatments prescribed on sequence analysis results |
|-----------------------|-----------------|------------------------------------------------------------------------------------------------------------------------|
| 1 F2                  | 3a              | Cost-effective treatment based on sequence analysis: 65% (naïve non-cirrhotic patients) vs 69% |
| 2 F4                  | 1a              | Cost-effective treatment based on sequence analysis: 65% (naïve non-cirrhotic patients) vs 69% |
| 3 F2                  | 4               | Cost-effective treatment based on sequence analysis: 65% (naïve non-cirrhotic patients) vs 69% |
| **Notes:**            |                 | *The most likely prescription based on reimbursement allowance rules at AIFA website.** |

**Abbreviations:** AIFA: Italian Regulatory Agency; DCC, discastructor; DAS, dasabuvir; HCV, hepatitis C virus; LDV, ledipasvir; OMB, ombitasvir; PTV, paritaprevir; RBV, ribavirin; Rtv, ritonavir; SIM, simeprevir; SOF, sofosbuvir; wk, weeks.

in efficacy which we gauged at our best, based on literature data, as ranging between 17% and 40% (Table 1). G1a was assigned by sequencing instead of G1b by commercial assays in eight out of nine cases with incorrect G1 subtype. This would have caused suboptimal treatment courses, with an expected decrease in efficacy from 5% to 7%. Conversely, in the single opposite case (G1b assignment instead of G1a), the consequence would have been a slight increase in costs and the requirement of ribavirin use (Table 2). For patients with G1 and indeterminate subtype, the choice of regimens would have targeted the subtype 1a option, with a potential sensible increase in costs (Table 2). Finally, the possible consequences of inappropriate prescription due to mixed HCV infections are shown in Table 3. In these cases, pan-genotypic regimens would be mandatory, with an increase in costs up to €32,000 per treatment.

The use of sequence analysis of HCV genotype, compared with LiPA-HCV genotype assay, would lead to a mean increase of efficacy (+1.42%) and per capita costs (+€1,280 per patient). The results of the cost-effectiveness analysis are presented in Table 4.

The 2.4% of the sensitivity analysis simulations led to a dominance of sequence analysis of HCV genotype compared with LiPA-HCV genotype assay, reducing costs and increasing efficacy, while the remaining 97.6% of the results showed an increase in costs and efficacy (between €1,269 and €4,617, and 1.43% and 3.88%) with incremental cost-effectiveness ratios between €845/efficacy unit and €2,009/efficacy unit.

**Discussion**

Although some studies found uninterpretable or indeterminate genotype assignments in varying percentages of assayed samples, especially in non-G1 HCV infections, the possible consequences of HCV genotype misclassification on treatments with DAAs were not yet evaluated and may have been perceived as a minor problem so far. However, in the new scenario of HCV therapy, the costs of genotyping by sequencing are definitely lower than those of DAA regimens, so that even a few treatment failures averted may make reassessing HCV genotype before DAAs very convenient.2 As a consequence, studies aimed at gauging the improvement of treatment outcomes by the systematic deployment of sequence genotype should be encouraged. We introduced mandatory sequencing assays of HCV prior to HCV therapy with DAAs at our site, and compared the results of all consecutive assays performed with previous routine genotype assessments, in an attempt to pinpoint all possible differences in treatment efficacy and on possible parallel cost savings obtained in this way. Although
Table 2 Consequences on prescription of interferon-free treatment regimens in case of inaccurate HCV genotype 1 subtype assignment

| Patient | META VIR Score | Versant HCV Genotype 2.0 Genotyping assay | Cost-effective treatment based on Versant HCV Genotype 2.0 assay* | Sequence results | Cost-effective treatment based on sequence analysis | Estimated efficacy of treatments prescribed on the basis of Versant HCV Genotype 2.0 assays vs treatments prescribed on sequence analysis results |
|---------|----------------|------------------------------------------|---------------------------------------------------------------|----------------|---------------------------------------------------|---------------------------------------------------------------------------------------------------------------|
| 1       | F3             | I                                        | Cost-effective treatment based on Versant HCV Genotype 2.0 assay* | 1a             | 12 wk PTV OMB/Rtv DAS RBV                           | No difference                                                                                                  |
| 2       | F3             | I                                        | Cost-effective treatment based on Versant HCV Genotype 2.0 assay* | 1a             | 12 wk PTV OMB/Rtv DAS RBV                           | No difference                                                                                                  |
| 3       | F3             | I                                        | Cost-effective treatment based on Versant HCV Genotype 2.0 assay* | 1a             | 12 wk PTV OMB/Rtv DAS RBV                           | No difference                                                                                                  |
| 4       | F3             | I                                        | Cost-effective treatment based on Versant HCV Genotype 2.0 assay* | 1b             | 12 wk PTV OMB/Rtv DAS RBV                           | Equivalent efficacy but more costly by €17,700                                                               |
| 5       | F3             | I                                        | Cost-effective treatment based on Versant HCV Genotype 2.0 assay* | 1b             | 12 wk PTV OMB/Rtv DAS RBV                           | Equivalent efficacy but more costly by €17,700                                                               |
| 6       | F3             | I                                        | Cost-effective treatment based on Versant HCV Genotype 2.0 assay* | 1b             | 12 wk PTV OMB/Rtv DAS RBV                           | Equivalent efficacy but more costly by €17,700                                                               |
| 7       | F3             | I                                        | Cost-effective treatment based on Versant HCV Genotype 2.0 assay* | 1b             | 12 wk PTV OMB/Rtv DAS RBV                           | Equivalent efficacy but more costly by €17,700                                                               |
| 8       | F3             | I                                        | Cost-effective treatment based on Versant HCV Genotype 2.0 assay* | 1b             | 12 wk PTV OMB/Rtv DAS RBV                           | Equivalent efficacy but more costly by €17,700                                                               |
| 9       | F3             | I                                        | Cost-effective treatment based on Versant HCV Genotype 2.0 assay* | 1b             | 12 wk PTV OMB/Rtv DAS RBV                           | Equivalent efficacy but more costly by €17,700                                                               |
| 10      | F3             | I                                        | Cost-effective treatment based on Versant HCV Genotype 2.0 assay* | 1b             | 12 wk PTV OMB/Rtv DAS RBV                           | Equivalent efficacy but more costly by €17,700                                                               |
| 11      | F3             | I                                        | Cost-effective treatment based on Versant HCV Genotype 2.0 assay* | 1b             | 12 wk PTV OMB/Rtv DAS RBV                           | Equivalent efficacy but more costly by €17,700                                                               |
| 12      | F3             | I                                        | Cost-effective treatment based on Versant HCV Genotype 2.0 assay* | 1b             | 12 wk PTV OMB/Rtv DAS RBV                           | Equivalent efficacy but more costly by €17,700                                                               |
| 13      | F3             | I                                        | Cost-effective treatment based on Versant HCV Genotype 2.0 assay* | 1b             | 12 wk PTV OMB/Rtv DAS RBV                           | Equivalent efficacy but more costly by €17,700                                                               |
| 14      | F3             | I                                        | Cost-effective treatment based on Versant HCV Genotype 2.0 assay* | 1b             | 12 wk PTV OMB/Rtv DAS RBV                           | Equivalent efficacy but more costly by €17,700                                                               |

Notes: *The most likely prescription based on reimbursement allowance rules at AIFA website.
Abbreviations: AIFA, Italian Regulatory Agency; DCV, daclatasvir; DAS, dasabuvir; HCV, hepatitis C virus; LDV, ledipasvir; NA, not applicable; OMB, ombitasvir; PTV, paritaprevir; RBV, ribavirin; Rtv, ritonavir; SOF, sofosbuvir; wk, weeks.
Table 3 Consequences on prescription of interferon-free treatment regimens in case of mixed infections by routine HCV genotyping

| Patient METAVIR score | Estimated efficacy of treatments prescribed on the basis of Versant HCV Genotype 2.0 assays vs treatments prescribed on sequence analysis results | Cost-effective treatment based on sequence analysis results | Cost-effective treatment based on Versant HCV Genotype 2.0 assays |
|-----------------------|---------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------|---------------------------------------------------------------|
| 1 F2 1a/1b 12 wk PTV OMB/Rtv DAS RBV €23,903 | No difference | Equivalent efficacy but more costly by €13,937 | Equivalent efficacy but more costly by €17,700 |
| 2 F2 1/3/4 12 wk SOF DCV €54,000 | Equivalent efficacy but more costly by €31,937 | €23,000 | €17,700 |
| 3 F2 1b 12 wk PTV OMB/Rtv DAS RBV €23,903 | No difference | Equivalent efficacy but more costly by €17,700 | Equivalent efficacy but more costly by €17,700 |
| 4 F4 1b/3 24 wk SOF DCV RBV €109,806 | No difference | Equivalent efficacy but more costly by €50,000 | Equivalent efficacy but more costly by €17,700 |

Notes: Some patients had two or three results at their preceding assay. The most likely prescription based on reimbursement allowance rules at AIFA website. Some patients had two or three results at their preceding assay. 

Abbreviations: AIFA, Italian Regulatory Agency; DCV, daclatasvir; DAS, dasabuvir; HCV, hepatitis C virus; LDV, ledipasvir; OMB, ombitasvir; PTV, paritaprevir; RBV, ribavirin; Rtv, ritonavir; SOF, sofosbuvir; wk, weeks.

We found percentages of HCV genotype/subtype misclassification approximately in line with those reported by others, identifying four main groups of failures in routine genotyping. In the first group, we included three patients with misclassified genotypes. These would have had the potential of causing remarkable reductions in efficacy – up to 40% – of their respective DAA treatments, which means a high likelihood of inducing at least one treatment failure. This first group alone justified our effort and covered all study expenses. In the second and third groups were included several cases of indeterminate subtype or subtype misclassification. These would not have caused a significant reduction in efficacy; however, significant increases in costs would have occurred, especially for patients receiving a diagnosis of genotype 1a instead of 1b, and unduly longer and more toxic treatments. In these patients, the reduction in potential toxicity was an added and precious value on the top of averted expenses. In the last group of patients, mixed infections would have invariably induced the prescription of pan-genotypic regimens, causing a remarkable increase in costs, at least 50% greater than necessary.

The cost-effectiveness results show an overall increase in terms of efficacy due to the use of sequence analysis of HCV genotype along with a slight increase in terms of costs. The cost per unit of efficacy gained is difficult to interpret due to the lack of threshold values associated with SVR at 12 weeks for HCV-infected patients.

The analysis performed does not consider the savings due to the mean efficacy increase and the need of further antiviral treatments and monitoring for patients not reaching SVR in the LiPA-HCV genotype assay scenario. Moreover, adverse events–related costs were not considered in the analysis due to the absence of interferon in the antiviral treatments considered (assuming similar safety profiles), which would, however, increase the direct medical costs due to retreatments. Further cost savings not considered in the analysis due to higher efficacy of treatments are those related to the lack of progression of HCV infection.

Future analyses should include a measurement of monitoring activities, adverse events management, and follow-up.

The main limit of the cost-effectiveness analysis performed is related to the short-term time horizon and the lack of use of effectiveness parameters that allow to interpret incre-
ment cost-effectiveness ratio of technology use based on national recognized thresholds (ie, quality adjusted life years).

Overall, our experience highlights the importance and convenience of accurate HCV genotyping before current DAA regimens. If wrong or incomplete, HCV genotype information would have caused a preventable risk of treatment failure. The relatively low incremental costs of HCV sequence analysis compared with the current costs of DAAs suggests that precise assignment of HCV genotype and subtype by sequencing may be beneficial until new and more potent pan-genotypic regimens will be available for all patients. Therefore, for a personalized and tailored therapy, genotype by sequencing should be performed in advance of first-line treatment with DAAs.

Conclusion

Further analyses on the cohort, considering a longer time horizon, should investigate if, as potentially suggested by the results of the analysis presented, the use of sequence analysis of HCV genotype would lead to a decrease in direct medical costs for the treatment of HCV-infected patients, due to savings for the lower number of retreated patients and lack of disease progression. Further research is warranted.

Disclosure

The authors report no conflicts of interest in this work.

References

1. Yang R, Cong X, Du S, Fei R, Rao H, Wei L. Performance comparison of the versant HCV genotype 2.0 assay (LiPA) and the Abbott real-time HCV genotype II assay for detecting hepatitis C virus genotype 6. J Clin Microbiol. 2014;52(10):3685–3692.
2. Ceccherini-Silberstein F, Di Maio VC, Aragri M, Ciotti M, Cento V, Perno CF. Hepatitis C virus gene sequencing as a tool for precise genotyping in the era of new direct antiviral agents. Hepatology. 2016;63(3):1058–1059.
3. Guelfo JR, Macias I, Neumark K, et al. Reassessment of genotype 1 hepatitis C virus subtype misclassification by LiPA 2.0: implications for direct-acting antiviral treatment. J Clin Microbiol. 2014;52(11):4027–4029.
4. Larrat S, Poveda JD, Coudret C, et al. Sequencing assays for failed genotyping with the versant hepatitis C virus genotype assay (LiPA), version 2.0. J Clin Microbiol. 2013;51(9):2815–2821.
5. González V, Gomes-Fernandes M, Bascuñana E, et al. Accuracy of a commercially available assay for HCV genotype typing and subtyping in the clinical practice. J Clin Virol. 2013;58(1):249–253.
6. Murphy DG, Willems B, Deschenes M, Hilzenrat N, Mousseau R, Sabbah S. Use of sequence analysis of the NS5B region for routine genotyping of hepatitis C virus with reference to C/E1 and 5′ untranslated region sequences. J Clin Microbiol. 2007;45(4):1102–1112
7. Pollicuta M, Cento V, Paba P, Perno CF, Ciotti M. Nucleotide polymorphisms in the 5′UTR region of HCV can affect the ability of two widely used assays to assign an HCV genotype. J Virol Methods. 2013;193(1):205–208.
8. Zeuzem S, Dusheiko GM, Salupere R, et al. VALENCE Investigators. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med. 2014;370(21):1993–2001.
9. AASLD/IDSA/IAS–USA. Recommendations for testing, managing, and treating hepatitis C. Available from: http://www.hcvguidelines.org. Accessed September 2015.
10. EASL. Recommendations on treatment of hepatitis C. Available from: http://www.easl.eu/research/our-contributions/clinical-practice-guidelines. Accessed September 2, 2015.
11. AIFA-AISF. Documento di indirizzo dell’Associazione Italiana per lo Studio del Fegato per l’uso razionale di antivirali diretti di seconda generazione nelle categorie di pazienti affetti da epatite C cronica ammesse alla rimborsabilità in Italia [Document for the rational use of second generation direct antivirals in chronic hepatitis C patients approved for reimbursement in Italy]. Available from: http://www.agenziafarmaco.gov.it. Accessed October 5, 2015.
12. Ávila AP, Agua-Doce I, Andrade A, Padua E. Hepatitis C virus subtyping based on sequencing of the C/E1 and NS5B genomic regions in comparison to a commercially available line probe assay. J Med Virol. 2013;85(5):815–822.
13. Boucherdeau F, Cantaloube JF, Chevaliez S, et al. Improvement of hepatitis C virus (HCV) genotype determination with the new version of the INNO-LiPA HCV assay. J Clin Microbiol. 2007;45(4):1140–1145.
14. Cai Q, Zhao Z, Liu Y, Shao X, Gao Z. Comparison of three different HCV genotyping methods: core, NS5B sequence analysis and line probe assay. Int J Mol Med. 2013;31(2):347–352.
15. Chevaliez S, Bouvier-Alias M, Brilot R, Pawlotsky JM. Hepatitis C virus (HCV) genotype 1 subtype identification in new HCV drug development and future clinical practice. PLoS One. 2009;4(12):e8209.
16. Vaghefi P, Marchadier E, Dussaix E, Roque-Afonso AM. Hepatitis C virus genotype typing: comparison of the Abbott RealTime HCV Genotype II assay and NS5B sequencing. Pathol Biol (Paris). 2010;58(2):175–178.
17. Quer J, Gregori J, Rodríguez-Frias F, et al. High-resolution hepatitis C virus subtyping using NS5B deep sequencing and phylogeny, an alternative to current methods. J Clin Microbiol. 2015;53(1):219–226.
18. Benedet M, Adachi D, Wong A, et al. The need for a sequencing-based assay to supplement the Abbott m2000 RealTime HCV Genotype II assay: a 1 year analysis. J Clin Virol. 2014;60(3):301–304.
19. Lawitz E, Sullivan G, Rodriguez-Torres M, et al. Exploratory trial of ombitasvir and ABR-450/rl with or without ribavirin for HCV genotype 1, 2, and 3 infection. J Infect. 2015;70(2):197–205.
20. Nelson DR, Cooper JN, Lalezari JP, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology. 2015;61(4):1127–1135.
21. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370(3):211–221.
22. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368(20):1878–1887.
23. Poordad F, Hedode C, Trinh R, et al. AET-450-r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014;370(21):1973–1982.
24. Ferenci P, Bernstein D, Lalezari J, et al. AET-450-r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014;370(21):1983–1992.
Cost-effectiveness of re-evaluating HCV genotype